Poolbeg Pharma announced significant advances and strategic expansions in its latest financial year, most notably with POLB 001 targeting a market opportunity exceeding $10 billion in cancer immunotherapy-induced Cytokine Release Syndrome (CRS).
In its 2023 fiscal year, Poolbeg Pharma PLC showcased a robust performance with strategic initiatives that significantly expand its market presence. Key highlights include the progression of POLB 001 into cancer therapy, targeting a potential market exceeding $10 billion, various patent filings enhancing its intellectual property portfolio, and noteworthy advancements in artificial intelligence-driven programmes. With a cash balance of £12.2 million, the company remains well-positioned to pursue its growth strategies.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
